Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1.

Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy. A number of IDO1 inhibitors have been identified, but only limited structural biology studies of IDO1 inhibitors are available to provide insights on the binding mechanism of IDO1. In this study, we present the structure of IDO1 in complex with 24, a NLG919 analogue with potent activity. The complex structure revealed the imidazole nitrogen atom of 24 to coordinate with the heme iron, and the imidazoleisoindole core situated in pocket A with the 1-cyclohexylethanol moiety extended to pocket B to interact with the surrounding residues. Most interestingly, 24 formed an extensive hydrogen bond network with IDO1, which is a distinct feature of IDO1/24 complex structure and is not observed in the other IDO1 complex structures. Further structure-activity relationship, UV spectra, and structural biology studies of several analogues of 24 demonstrated that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivatives. These results are expected to facilitate the structure-based drug design of new IDO inhibitors.

[1]  P. Zwart,et al.  Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.

[2]  M. Sono,et al.  Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. , 1989, Biochemistry.

[3]  B. Kuhn,et al.  Intramolecular hydrogen bonding in medicinal chemistry. , 2010, Journal of medicinal chemistry.

[4]  Qian Wang,et al.  Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.

[5]  P. Verhoest,et al.  Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. , 2015, Journal of medicinal chemistry.

[6]  M. Tsunoda,et al.  (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. , 1999, Bioorganic & medicinal chemistry letters.

[7]  J. McCarter,et al.  Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. , 2011, Biochimica et biophysica acta.

[8]  J. Fridman,et al.  Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors , 2010, Molecular Cancer Therapeutics.

[9]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[10]  Y. Chao,et al.  Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[11]  I. D. de Esch,et al.  4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists. , 2008, Journal of medicinal chemistry.

[12]  J. Dunbar,et al.  The design and synthesis of sulfonamides as caspase-1 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[13]  G. Bricogne,et al.  Achieving High Quality Ligand Chemistry in Protein-Ligand Crystal Structures for Drug Design , 2015 .

[14]  J. Dawson,et al.  Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme. , 1982, The Journal of biological chemistry.

[15]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[16]  J. Sredy,et al.  Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications. , 2004, Bioorganic & medicinal chemistry.

[17]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[18]  Judith M. LaLonde,et al.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. , 2008, Journal of medicinal chemistry.

[19]  Masataka Harada,et al.  Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. , 2003, Journal of medicinal chemistry.

[20]  Milton W. Taylor,et al.  Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.

[21]  Adam Ibrahim,et al.  Application of hydrogen bonding calculations in property based drug design. , 2002, Drug discovery today.

[22]  George C Schatz,et al.  Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy. , 2009, Analytical chemistry.

[23]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[24]  V. Zoete,et al.  Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. , 2012, Journal of medicinal chemistry.

[25]  S. Sligar,et al.  Substrate interaction with cytochrome P-450. , 1981, Pharmacology & therapeutics.

[26]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[27]  M. Baccarani,et al.  The role of indoleamine 2 , 3-dioxygenase in the induction of immune tolerance : focus on hematology , 2008 .

[28]  Tetsuya Kohno,et al.  Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.

[29]  Clemens Vonrhein,et al.  Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER , 2012, Acta crystallographica. Section D, Biological crystallography.

[30]  C. Sheridan.  IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.

[31]  Charles J. Link,et al.  Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. , 2013 .

[32]  Wladek Minor,et al.  Protein crystallography for aspiring crystallographers or how to avoid pitfalls and traps in macromolecular structure determination , 2013, The FEBS journal.

[33]  Matthew P Jacobson,et al.  Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.

[34]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[35]  Olivier Michielin,et al.  Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.

[36]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[37]  Vincent Breton,et al.  PDB_REDO: automated re-refinement of X-ray structure models in the PDB , 2009, Journal of applied crystallography.

[38]  Richard Svensson,et al.  Impact of Stereospecific Intramolecular Hydrogen Bonding on Cell Permeability and Physicochemical Properties , 2014, Journal of medicinal chemistry.

[39]  S. McCleary,et al.  Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. , 2001, Journal of medicinal chemistry.

[40]  H. Rammensee,et al.  Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? , 2009, Nature Reviews Cancer.

[41]  Takashi Otsuki,et al.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Walker,et al.  Expression and purification of recombinant human indoleamine 2, 3-dioxygenase. , 2000, Protein expression and purification.

[43]  Stephen F Martin,et al.  Preorganization in biological systems: Are conformational constraints worth the energy? , 2007 .